Drug Landscape ›
Estradiol 2 MG ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 10
Most-reported reactions
Blood Glucose Increased — 1 report (10%) Cardiac Disorder — 1 report (10%) Chronic Obstructive Pulmonary Disease — 1 report (10%) Diarrhoea — 1 report (10%) Disease Progression — 1 report (10%) Dry Skin — 1 report (10%) Erythema — 1 report (10%) Faeces Discoloured — 1 report (10%) Feeling Hot — 1 report (10%) Frequent Bowel Movements — 1 report (10%)
Source database →
Estradiol 2 MG in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Estradiol 2 MG approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Estradiol 2 MG in United States?
University Hospital, Angers is the originator. The local marketing authorisation holder may differ — check the official source linked above.